COMPANY

Ideal Medical Technologies

Profile checked Oct 10, 2026

Keywords: Type 2 Diabetes Mellitus Type 1 Diabetes Type 2 Diabetes Stress Induced Hyperglycemia Type 1 Diabetes Mellitus FUSION closed loop glucose control system

3Trials (company is sponsor)2NIH grants

Timeline

2026-07 Trial start Not phased (device or behavioral study): Closed Loop Glucose Control in a Simulated ICU Setting source ↗
Nov 8, 2022 Trial start Not phased (device or behavioral study): Closed Loop Glucose Control in Patients With Type 1 and Type 2 Diabetes source ↗
May 9, 2022 Trial start Not phased (device or behavioral study): Closed Loop Glucose Control in Patients With Type 2 Diabetes source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Not phased · Closed Loop Glucose Control in a Simulated ICU Setting · NCT07646067

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT07646067	Closed Loop Glucose Control in a Simulated ICU Setting	Not phased (device or behavioral study)	Not yet recruiting	2026-07	2026-12 (estimated)
NCT05386849	Closed Loop Glucose Control in Patients With Type 2 Diabetes	Not phased (device or behavioral study)	Completed	May 9, 2022	Jul 19, 2022 (actual)
NCT05644730	Closed Loop Glucose Control in Patients With Type 1 and Type 2 Diabetes	Not phased (device or behavioral study)	Completed	Nov 8, 2022	Apr 21, 2023 (actual)

NIH awards 2

Annual award amounts. Total $1.9M.

Jun 2, 2023 NIH award 5R44DK133084-02 FY2023: $931,064 awarded for that fiscal year; activity R44 (SBIR); PI DEJOURNETT, LEON; recipient as written: IDEAL MEDICAL TECHNOLOGIES, INC., ASHEVILLE, NC. Demonstration of the Feasibili source ↗
May 31, 2022 NIH award 1R44DK133084-01 FY2022: $958,212 awarded for that fiscal year; activity R44 (SBIR); PI DEJOURNETT, LEON; recipient as written: IDEAL MEDICAL TECHNOLOGIES, INC., ASHEVILLE, NC. Demonstration of the Feasibili source ↗